Anirban Maitra: An Open Access review on current status of KRAS inhibitors, resistance drivers and potential combinations
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X:
“An Open Access review on current status of KRAS inhibitors, resistance drivers and potential combinations from Der Lab at UNC, Channing Der, Bjoern Papke and colleagues.
Charité – Universitätsmedizin Berlin in Trends in Cancer.
As always very informative illustrations:
A: Frequency of KRAS Allelic alterations across various cancers.
B: Current portfolio of KRAS inhibitors separated by allele specific and agnostic compounds.
C: Common mechanisms of genomic and non genomic resistance.
D: Potential combinations that are being trialed in preclinical setting and in the clinic.”
KRAS inhibitors: resistance drivers and combinatorial strategies
Authors: Tamara Isermann, Christine Sers, Channing J. Der, Bjoern Papke
Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023